Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock

Published 19/03/2025, 21:36
Achieve Life Sciences CEO Richard Stewart purchases $28,598 in stock

Richard Stewart, the Chief Executive Officer of Achieve Life Sciences, Inc. (NASDAQ:ACHV), recently acquired 10,000 shares of the company’s common stock. The purchase, which took place on March 17, 2025, was made at a price of $2.8598 per share, totaling $28,598. The timing is notable as the stock is currently trading near its 52-week low of $2.51, with the current price at $2.67. Following this transaction, Stewart’s direct holdings increased to 60,876 shares in the $93 million market cap company.

In addition to his direct ownership, Stewart also holds shares indirectly. His spouse owns 359 shares, and Ricanto Limited, where Stewart is a principal owner, holds 882 shares. These transactions reflect Stewart’s continued investment in Achieve Life Sciences, a company specializing in in vitro and in vivo diagnostic substances. According to InvestingPro, analysts maintain a strong buy consensus with price targets ranging from $10 to $30, though the company’s financial health score currently stands at "Fair." Additional insights and detailed analysis are available in the comprehensive Pro Research Report.

In other recent news, Achieve Life Sciences reported fourth-quarter earnings that did not meet analyst expectations, recording a loss of $0.36 per share compared to the anticipated $0.34 loss. The company reported total operating expenses of $12.2 million and a net loss of $12.4 million for the quarter. Achieve Life Sciences ended the year with $34.4 million in cash, cash equivalents, and marketable securities. Despite the earnings miss, the company plans to submit a new drug application for cytisinicline to the U.S. Food and Drug Administration by the end of the second quarter of 2025. Achieve Life Sciences has completed enrollment in its ORCA-OL long-term exposure trial, meeting the requirement of 300 participants. Positive outcomes were announced from two data safety monitoring committee reviews of the ORCA-OL trial, with no safety concerns identified. Additionally, the company recently appointed two new board members and a new Chief Financial Officer to support its strategic initiatives and potential commercialization efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.